Please login to the form below

Not currently logged in
Email:
Password:

BIIB059

This page shows the latest BIIB059 news and features for those working in and with pharma, biotech and healthcare.

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... added. In addition to BIIB059, Biogen also has another investigational lupus asset – dapirolizumab pegol –

Latest news

  • Biogen scores mid-stage trial win for lupus drug BIIB059 Biogen scores mid-stage trial win for lupus drug BIIB059

    The SLE arm only tested the highest 450mg dose of BIIB059, and showed the drug reduced the number of joints with active inflammation compared to placebo at 24 weeks. ... We are excited by the LILAC study results, and the potential for BIIB059 to be a

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...